{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:05:16Z","timestamp":1793135116926,"version":"4.5.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rivaroxaban is a direct, oral factor Xa inhibitor that is used for the prevention and treatment of various thromboembolic disorders. Several preclinical and clinical studies have utilized specific molecules as biomarkers to investigate the potential role of rivaroxaban beyond its anticoagulant activity and across a range of biological processes. The aim of this review is to summarize the existing evidence regarding the use of blood-based biomarkers to characterize the effects of rivaroxaban on coagulation and other pathways, including platelet activation, inflammation and endothelial effects. After a literature search using PubMed, almost 100 preclinical and clinical studies were identified that investigated the effects of rivaroxaban using molecular biomarkers. In agreement with the preclinical data, clinical studies reported a trend for reduction in the blood concentrations of D-dimers, thrombin\u2013antithrombin complex and prothrombin fragment 1\u2009+\u20092 following treatment with rivaroxaban in both healthy individuals and those with various chronic conditions. Preclinical and also some clinical studies have also reported a potential impact of rivaroxaban on the concentrations of platelet activation biomarkers (von Willebrand factor, P-selectin and thrombomodulin), endothelial activation biomarkers (matrix metalloproteinase-9, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1) and inflammation biomarkers (interleukin-6, tumor necrosis factor-\u03b1 and monocyte chemoattractant protein-1). Based on the results of biomarker studies, molecular biomarkers can be used in addition to traditional coagulation assays to increase the understanding of the anticoagulation effects of rivaroxaban. Moreover, there is preliminary evidence to suggest that rivaroxaban may have an impact on the biological pathways of platelet activation, endothelial activation and inflammation; however, owing to paucity of clinical data to investigate the trends reported in preclinical studies, further investigation is required to clarify these observations.<\/jats:p>","DOI":"10.1007\/s11239-023-02776-z","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T18:02:45Z","timestamp":1675706565000},"page":"449-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9708-691X","authenticated-orcid":false,"given":"Sonja","family":"Schiffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Heitmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"issue":"(suppl_Q)","key":"2776_CR1","doi-asserted-by":"publisher","first-page":"Q3","DOI":"10.1016\/S1520-765X(01)90034-3","volume":"3","author":"H Rasche","year":"2001","unstructured":"Rasche H (2001) Haemostasis and thrombosis: an overview. Eur Heart J Suppl. 3((suppl_Q)):Q3-7","journal-title":"Eur Heart J Suppl."},{"issue":"5","key":"2776_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1503\/cjs.007310","volume":"54","author":"WD Fisher","year":"2011","unstructured":"Fisher WD (2011) Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Can J Surg 54(5):344\u2013351","journal-title":"Can J Surg"},{"issue":"9658","key":"2776_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","volume":"373","author":"T Watson","year":"2009","unstructured":"Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: virchow\u2019s triad revisited. Lancet 373(9658):155\u2013166","journal-title":"Lancet"},{"issue":"2","key":"2776_CR4","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1097\/MJT.0000000000000913","volume":"26","author":"C Pop","year":"2019","unstructured":"Pop C, Matei C, Petris A (2019) Anticoagulation in acute coronary syndrome: review of major therapeutic advances. Am J Ther 26(2):e184\u2013e197","journal-title":"Am J Ther"},{"issue":"8","key":"2776_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.7326\/0003-4819-126-8-199704150-00009","volume":"126","author":"DP Thomas","year":"1997","unstructured":"Thomas DP, Roberts HR (1997) Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 126(8):638\u2013644","journal-title":"Ann Intern Med"},{"issue":"12","key":"2776_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","volume":"61","author":"D Kubitza","year":"2005","unstructured":"Kubitza D et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59\u20137939 \u2013 an oral, direct Factor Xa inhibitor \u2013 after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873\u2013880","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2776_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4103\/0019-5049.144643","volume":"58","author":"S Palta","year":"2014","unstructured":"Palta S, Saroa R, Palta A (2014) Overview of the coagulation system. Indian J Anaesth 58(5):515\u2013523","journal-title":"Indian J Anaesth"},{"key":"2776_CR8","unstructured":"FDA-NIH Biomarker Working Group, BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/?report=classic. Accessed 11 Feb 2019."},{"issue":"14","key":"2776_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319\u20131330","journal-title":"N Engl J Med"},{"issue":"6","key":"2776_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/bloodadvances.2017013573","volume":"2","author":"O Borst","year":"2018","unstructured":"Borst O et al (2018) Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. Blood Adv 2(6):715\u2013730","journal-title":"Blood Adv"},{"key":"2776_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01731","author":"K G\u00f6bel","year":"2018","unstructured":"G\u00f6bel K et al (2018) The coagulation factors fibrinogen, thrombin, and factor XII in inflammatory disorders\u2014a systematic review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.01731","journal-title":"Front Immunol"},{"issue":"4","key":"2776_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1160\/TH13-09-0730","volume":"111","author":"CT Esmon","year":"2014","unstructured":"Esmon CT (2014) Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 111(4):625\u2013633","journal-title":"Thromb Haemost"},{"issue":"2","key":"2776_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1208\/s12248-011-9265-x","volume":"13","author":"JPF Bai","year":"2011","unstructured":"Bai JPF et al (2011) Translational biomarkers: from preclinical to clinical a report of 2009 AAPS\/ACCP Biomarker Workshop. AAPS J 13(2):274\u2013283","journal-title":"AAPS J"},{"issue":"6","key":"2776_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","volume":"127","author":"MM Samama","year":"2011","unstructured":"Samama MM (2011) The mechanism of action of rivaroxaban \u2013 an oral, direct Factor Xa inhibitor\u2013compared with other anticoagulants. Thromb Res 127(6):497\u2013504","journal-title":"Thromb Res"},{"issue":"3","key":"2776_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","volume":"30","author":"E Perzborn","year":"2010","unstructured":"Perzborn E et al (2010) Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 30(3):376\u2013381","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2776_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","volume":"3","author":"E Perzborn","year":"2005","unstructured":"Perzborn E et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20137939\u2014an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(3):514\u2013521","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2776_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.thromres.2014.11.037","volume":"135","author":"DR Arachchillage","year":"2015","unstructured":"Arachchillage DR et al (2015) Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res 135(2):388\u2013393","journal-title":"Thromb Res"},{"issue":"9","key":"2776_CR18","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1161\/STROKEAHA.117.017981","volume":"48","author":"M Ebner","year":"2017","unstructured":"Ebner M et al (2017) Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. Stroke 48(9):2457\u20132463","journal-title":"Stroke"},{"issue":"2","key":"2776_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.healun.2010.08.027","volume":"30","author":"M Gheorghiade","year":"2011","unstructured":"Gheorghiade M et al (2011) Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. J Heart Lung Transplant 30(2):218\u2013226","journal-title":"J Heart Lung Transplant"},{"issue":"11","key":"2776_CR20","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1177\/0091270007302952","volume":"47","author":"J Graff","year":"2007","unstructured":"Graff J et al (2007) Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 47(11):1398\u20131407","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"2776_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2141.2010.08433.x","volume":"151","author":"L Green","year":"2010","unstructured":"Green L et al (2010) The impact of elective knee\/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol 151(5):469\u2013476","journal-title":"Br J Haematol"},{"key":"2776_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2016.10.011","volume":"148","author":"J Hagii","year":"2016","unstructured":"Hagii J et al (2016) Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: insight from its serial measurement. Thromb Res 148:9\u201314","journal-title":"Thromb Res"},{"issue":"4","key":"2776_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s11239-017-1492-2","volume":"43","author":"TA Helin","year":"2017","unstructured":"Helin TA et al (2017) Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement. J Thromb Thrombolysis 43(4):562\u2013569","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2776_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jjcc.2015.12.009","volume":"68","author":"Y Hitaka","year":"2016","unstructured":"Hitaka Y et al (2016) Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation. J Cardiol 68(6):529\u2013535","journal-title":"J Cardiol"},{"issue":"6","key":"2776_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1160\/TH12-05-0310","volume":"108","author":"MY Chan","year":"2012","unstructured":"Chan MY et al (2012) Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thromb Haemost 108(6):1180\u20131191","journal-title":"Thromb Haemost"},{"issue":"9","key":"2776_CR26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1007\/s00380-017-0962-y","volume":"32","author":"H Katoh","year":"2017","unstructured":"Katoh H, Nozue T, Michishita I (2017) Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation. Heart Vessels 32(9):1130\u20131136","journal-title":"Heart Vessels"},{"issue":"5","key":"2776_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00380-016-0912-0","volume":"32","author":"F Kitagawa","year":"2017","unstructured":"Kitagawa F et al (2017) Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population. Heart Vessels 32(5):609\u2013617","journal-title":"Heart Vessels"},{"issue":"1","key":"2776_CR28","first-page":"156","volume":"106","author":"H Mani","year":"2011","unstructured":"Mani H et al (2011) Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 106(1):156\u2013164","journal-title":"Thromb Haemost"},{"issue":"10","key":"2776_CR29","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1515\/cclm-2012-0055","volume":"50","author":"PJ Molenaar","year":"2012","unstructured":"Molenaar PJ, Dinkelaar J, Leyte A (2012) Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 50(10):1799\u20131807","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"2776_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jjcc.2014.07.021","volume":"65","author":"Y Nakano","year":"2015","unstructured":"Nakano Y et al (2015) Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban. J Cardiol 65(3):185\u2013190","journal-title":"J Cardiol"},{"issue":"2","key":"2776_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MBC.0000000000000203","volume":"26","author":"E Oswald","year":"2015","unstructured":"Oswald E et al (2015) Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study. Blood Coagul Fibrinolysis 26(2):136\u2013144","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"2776_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/bjh.14230","volume":"179","author":"S Platton","year":"2017","unstructured":"Platton S, Bowles L, MacCallum P (2017) Effects of rivaroxaban on routine coagulation screening tests using commonly used reagents. Br J Haematol 179(3):511\u2013513","journal-title":"Br J Haematol"},{"issue":"6","key":"2776_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/ejh.13050","volume":"100","author":"J Pratt","year":"2018","unstructured":"Pratt J, Crispin P (2018) Screening test for direct oral anticoagulants with the dilute Russell viper venom time. Eur J Haematol 100(6):567\u2013574","journal-title":"Eur J Haematol"},{"issue":"4","key":"2776_CR34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11239-017-1495-z","volume":"43","author":"B Steppich","year":"2017","unstructured":"Steppich B et al (2017) Effect of the FXa inhibitors rivaroxaban and apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis 43(4):490\u2013497","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2776_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.dmpk.2018.02.002","volume":"33","author":"S Suzuki","year":"2018","unstructured":"Suzuki S et al (2018) An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1). Drug Metab Pharmacokinet 33(4):188\u2013193","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"2776_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jjcc.2014.08.006","volume":"65","author":"K Tajiri","year":"2015","unstructured":"Tajiri K et al (2015) Impact of rivaroxaban compared with warfarin on the coagulation status in Japanese patients with non-valvular atrial fibrillation: a preliminary analysis of the prothrombin fragment 1+2 levels. J Cardiol 65(3):191\u2013196","journal-title":"J Cardiol"},{"issue":"8","key":"2776_CR37","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/MBC.0000000000000509","volume":"27","author":"H Wan","year":"2016","unstructured":"Wan H et al (2016) An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. Blood Coagul Fibrinolysis 27(8):882\u2013885","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"2776_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1160\/TH15-01-0061","volume":"114","author":"P Vranckx","year":"2015","unstructured":"Vranckx P et al (2015) Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease the X-PLORER trial. Thromb Haemost 114(2):258\u2013267","journal-title":"Thromb Haemost"},{"issue":"6","key":"2776_CR39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","volume":"130","author":"J Douxfils","year":"2012","unstructured":"Douxfils J et al (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130(6):956\u2013966","journal-title":"Thromb Res"},{"issue":"8","key":"2776_CR40","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/MBC.0b013e32834cb30e","volume":"22","author":"TJ Parry","year":"2011","unstructured":"Parry TJ et al (2011) Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul Fibrinolysis 22(8):720\u2013726","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"2776_CR41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1160\/TH11-04-0275","volume":"106","author":"AC Rosenkranz","year":"2011","unstructured":"Rosenkranz AC, Schror K, Rauch BH (2011) Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells. Thromb Haemost 106(3):561\u2013562","journal-title":"Thromb Haemost"},{"issue":"11","key":"2776_CR42","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1182\/blood-2013-08-523936","volume":"123","author":"EM Sparkenbaugh","year":"2014","unstructured":"Sparkenbaugh EM et al (2014) Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 123(11):1747\u20131756","journal-title":"Blood"},{"key":"2776_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.thromres.2019.04.033","volume":"179","author":"HY Lim","year":"2019","unstructured":"Lim HY et al (2019) A review of global coagulation assays - Is there a role in thrombosis risk prediction? Thromb Res 179:45\u201355","journal-title":"Thromb Res"},{"issue":"4","key":"2776_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1536\/ihj.20-041","volume":"61","author":"N Hirota","year":"2020","unstructured":"Hirota N et al (2020) Analysis of bioMARKer distribution and individual reproducibility under rivaroxaban treatment in japanese patients with non-valvular atrial fibrillation (R-MARK Study, CVI ARO2). Int Heart J 61(4):695\u2013704","journal-title":"Int Heart J"},{"issue":"3","key":"2776_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1160\/TH06-11-0620","volume":"97","author":"BJ Biemond","year":"2007","unstructured":"Biemond BJ et al (2007) Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)\u2013an oral, direct factor Xa inhibitor. Thromb Haemost 97(3):471\u2013477","journal-title":"Thromb Haemost"},{"issue":"3","key":"2776_CR46","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1161\/STROKEAHA.112.675231","volume":"44","author":"W Zhou","year":"2013","unstructured":"Zhou W et al (2013) Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 44(3):771\u2013778","journal-title":"Stroke"},{"issue":"12","key":"2776_CR47","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.5858\/arpa.2013-0750-OA","volume":"138","author":"RC Gosselin","year":"2014","unstructured":"Gosselin RC et al (2014) Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med 138(12):1680\u20131684","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"2776_CR48","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1172\/JCI108902","volume":"60","author":"DL Aronson","year":"1977","unstructured":"Aronson DL et al (1977) Generation of the combined prothrombin activation peptide (F1\u20132) during the clotting of blood and plasma. J Clin Invest 60(6):1410\u20131418","journal-title":"J Clin Invest"},{"issue":"2","key":"2776_CR49","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11239-020-02079-7","volume":"50","author":"EI Ueno","year":"2020","unstructured":"Ueno EI et al (2020) Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban. J Thromb Thrombolysis 50(2):371\u2013379","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"2776_CR50","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1111\/jth.12726","volume":"12","author":"S Weisshaar","year":"2014","unstructured":"Weisshaar S et al (2014) Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. J Thromb Haemost 12(11):1850\u20131860","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2776_CR51","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/jth.13213","volume":"14","author":"S Brunner-Ziegler","year":"2016","unstructured":"Brunner-Ziegler S et al (2016) Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects. J Thromb Haemost 14(2):316\u2013323","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2776_CR52","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/1076029616648407","volume":"22","author":"J Liles","year":"2016","unstructured":"Liles J et al (2016) Increased level of thrombotic biomarkers in patients with atrial fibrillation despite traditional and new anticoagulant therapy. Clin Appl Thromb Hemost 22(8):743\u2013748","journal-title":"Clin Appl Thromb Hemost"},{"key":"2776_CR53","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/07853890.2018.1495337","volume":"50","author":"K Miyazawa","year":"2018","unstructured":"Miyazawa K et al (2018) Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). Ann Med 50:511\u2013518","journal-title":"Ann Med"},{"issue":"1","key":"2776_CR54","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1055\/s-0040-1701206","volume":"4","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P et al (2020) Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial. TH Open 4(1):e20\u2013e32","journal-title":"TH Open"},{"issue":"10","key":"2776_CR55","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/clinchem\/34.10.2058","volume":"34","author":"JA Hoek","year":"1988","unstructured":"Hoek JA et al (1988) Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 34(10):2058\u20132062","journal-title":"Clin Chem"},{"issue":"7","key":"2776_CR56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.20452\/pamw.162","volume":"117","author":"E Stepien","year":"2007","unstructured":"Stepien E et al (2007) Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease. Pol Arch Med Wewn 117(7):297\u2013305","journal-title":"Pol Arch Med Wewn"},{"issue":"2","key":"2776_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ajh.2830380203","volume":"38","author":"K Deguchi","year":"1991","unstructured":"Deguchi K et al (1991) Dynamic fluctuations in blood of thrombin\/antithrombin III complex (TAT). Am J Hematol 38(2):86\u201389","journal-title":"Am J Hematol"},{"issue":"4","key":"2776_CR58","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1160\/TH15-08-0631","volume":"115","author":"M Dittmeier","year":"2016","unstructured":"Dittmeier M et al (2016) Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism. Thromb Haemost 115(4):835\u2013843","journal-title":"Thromb Haemost"},{"issue":"2","key":"2776_CR59","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","volume":"242","author":"T Hara","year":"2015","unstructured":"Hara T et al (2015) Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 242(2):639\u2013646","journal-title":"Atherosclerosis"},{"issue":"8","key":"2776_CR60","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","volume":"3","author":"SR Coughlin","year":"2005","unstructured":"Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3(8):1800\u20131814","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2776_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/ATVBAHA.118.311655","volume":"39","author":"JJ Posma","year":"2019","unstructured":"Posma JJ et al (2019) Roles of coagulation proteases and PARs (Protease-Activated Receptors) in mouse models of inflammatory diseases. Arterioscler Thromb Vasc Biol 39(1):13\u201324","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"2776_CR62","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1073\/pnas.97.10.5255","volume":"97","author":"E Camerer","year":"2000","unstructured":"Camerer E, Huang W, Coughlin SR (2000) Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 97(10):5255\u20135260","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2776_CR63","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.atherosclerosis.2010.07.017","volume":"212","author":"G Demetz","year":"2010","unstructured":"Demetz G et al (2010) Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells. Atherosclerosis 212(2):466\u2013471","journal-title":"Atherosclerosis"},{"key":"2776_CR64","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.yjmcc.2018.09.003","volume":"123","author":"CC Chung","year":"2018","unstructured":"Chung CC et al (2018) Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis. J Mol Cell Cardiol 123:128\u2013138","journal-title":"J Mol Cell Cardiol"},{"key":"2776_CR65","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.brainres.2019.05.024","volume":"1719","author":"C Puech","year":"2019","unstructured":"Puech C et al (2019) Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin\/PAR-1 pathway. Brain Res 1719:57\u201363","journal-title":"Brain Res"},{"issue":"4","key":"2776_CR66","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1161\/CIRCRESAHA.119.315099","volume":"126","author":"T Petzold","year":"2020","unstructured":"Petzold T et al (2020) Rivaroxaban Reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1. Circ Res 126(4):486\u2013500","journal-title":"Circ Res"},{"issue":"5\u20136","key":"2776_CR67","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/0049-3848(79)90177-4","volume":"15","author":"PJ Gaffney","year":"1979","unstructured":"Gaffney PJ, Joe F (1979) The lysis of crosslinked human fibrin by plasmin yields initially a single molecular complex D dimer-E. Thromb Res 15(5\u20136):673\u2013687","journal-title":"Thromb Res"},{"issue":"3","key":"2776_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/ehjcvp\/pvv039","volume":"2","author":"AY Soomro","year":"2016","unstructured":"Soomro AY et al (2016) The current role and future prospects of D-dimer biomarker. Eur Heart J Cardiovasc Pharmacother 2(3):175\u2013184","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9","key":"2776_CR69","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.amjcard.2018.07.032","volume":"122","author":"F AlKhalfan","year":"2018","unstructured":"AlKhalfan F et al (2018) D-Dimer levels and effect of rivaroxaban on those levels and outcomes in patients with acute coronary syndrome (an ATLAS ACS-TIMI 46 trial substudy). Am J Cardiol 122(9):1459\u20131464","journal-title":"Am J Cardiol"},{"issue":"4","key":"2776_CR70","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/rth2.12142","volume":"2","author":"LJJ Scheres","year":"2018","unstructured":"Scheres LJJ et al (2018) Measurement of coagulation factors during rivaroxaban and apixaban treatment: results from two crossover trials. Res Pract Thromb Haemost 2(4):689\u2013695","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2776_CR71","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1055\/s-0040-1705137","volume":"4","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC et al (2020) Modified IMPROVE VTE risk score and elevated D-dimer identify a High venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open 4(1):e59\u2013e65","journal-title":"TH Open"},{"key":"2776_CR72","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ejhf.2003","volume":"23","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP et al (2020) Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. Eur J Heart Fail 23:648\u2013656","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2776_CR73","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2015-04-638387","volume":"127","author":"B Estevez","year":"2016","unstructured":"Estevez B et al (2016) Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation. Blood 127(5):626\u2013636","journal-title":"Blood"},{"key":"2776_CR74","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.phrs.2013.05.002","volume":"74","author":"U Flierl","year":"2013","unstructured":"Flierl U et al (2013) The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure. Pharmacol Res 74:49\u201355","journal-title":"Pharmacol Res"},{"issue":"Pt A","key":"2776_CR75","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.phrs.2016.09.035","volume":"113","author":"P Pignatelli","year":"2016","unstructured":"Pignatelli P et al (2016) Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. Pharmacol Res 113(Pt A):484\u2013489","journal-title":"Pharmacol Res"},{"issue":"3","key":"2776_CR76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11239-012-0727-5","volume":"34","author":"SM Ringwala","year":"2012","unstructured":"Ringwala SM, Dibattiste PM, Schneider DJ (2012) Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis 34(3):291\u2013296","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"2776_CR77","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/M19-0291","volume":"171","author":"J Ordi-Ros","year":"2019","unstructured":"Ordi-Ros J et al (2019) Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 171(10):685\u2013694","journal-title":"Ann Intern Med"},{"issue":"3","key":"2776_CR78","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11239-015-1245-z","volume":"40","author":"N Zemer-Wassercug","year":"2015","unstructured":"Zemer-Wassercug N et al (2015) The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. J Thromb Thrombolysis 40(3):340\u2013346","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2776_CR79","doi-asserted-by":"publisher","first-page":"895","DOI":"10.4049\/jimmunol.155.2.895","volume":"155","author":"LE Sower","year":"1995","unstructured":"Sower LE et al (1995) Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 155(2):895\u2013901","journal-title":"J Immunol"},{"issue":"8","key":"2776_CR80","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1084\/jem.20071427","volume":"205","author":"D Chen","year":"2008","unstructured":"Chen D et al (2008) Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med 205(8):1739\u20131746","journal-title":"J Exp Med"},{"key":"2776_CR81","doi-asserted-by":"publisher","first-page":"165453","DOI":"10.1155\/2013\/165453","volume":"2013","author":"H Yang","year":"2013","unstructured":"Yang H et al (2013) Induction of tumor necrosis factor (TNF) release from subtypes of T cells by agonists of proteinase activated receptors. Mediators Inflamm 2013:165453","journal-title":"Mediators Inflamm"},{"issue":"9","key":"2776_CR82","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","volume":"118","author":"JH Foley","year":"2016","unstructured":"Foley JH, Conway EM (2016) Cross talk pathways between coagulation and inflammation. Circ Res 118(9):1392\u20131408","journal-title":"Circ Res"},{"key":"2776_CR83","doi-asserted-by":"publisher","first-page":"35580","DOI":"10.1038\/srep35580","volume":"6","author":"F Sanada","year":"2016","unstructured":"Sanada F et al (2016) Activated factor X induces endothelial cell senescence through IGFBP-5. Sci Rep 6:35580","journal-title":"Sci Rep"},{"key":"2776_CR84","doi-asserted-by":"publisher","first-page":"106679","DOI":"10.1016\/j.vph.2020.106679","volume":"130","author":"E Wypasek","year":"2020","unstructured":"Wypasek E et al (2020) Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. Vascul Pharmacol 130:106679","journal-title":"Vascul Pharmacol"},{"key":"2776_CR85","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.thromres.2016.04.008","volume":"142","author":"P Ellinghaus","year":"2016","unstructured":"Ellinghaus P et al (2016) Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran. Thromb Res 142:44\u201351","journal-title":"Thromb Res"},{"issue":"4","key":"2776_CR86","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.thromres.2015.01.023","volume":"135","author":"Y Ishibashi","year":"2015","unstructured":"Ishibashi Y, Matsui T, Fukami K, Ueda S, Okuda S, Yamagishi S (2015) Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin\/protease-activated receptor-2 system. Thromb Res 135(4):770\u20133","journal-title":"Thromb Res"},{"issue":"12","key":"2776_CR87","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/bcp.13383","volume":"83","author":"G Monux","year":"2017","unstructured":"Monux G et al (2017) FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms. Br J Clin Pharmacol 83(12):2661\u20132670","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2776_CR88","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2162-3619-3-30","volume":"3","author":"M Laurent","year":"2014","unstructured":"Laurent M et al (2014) Comparative study of the effect of rivaroxaban and fondaparinux on monocyte\u2019s coagulant activity and cytokine release. Exp Hematol Oncol 3(1):30","journal-title":"Exp Hematol Oncol"},{"key":"2776_CR89","doi-asserted-by":"publisher","first-page":"432080","DOI":"10.1155\/2011\/432080","volume":"2011","author":"Q Zhou","year":"2011","unstructured":"Zhou Q et al (2011) Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011:432080","journal-title":"Mediators Inflamm"},{"key":"2776_CR90","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ijcard.2016.06.212","volume":"220","author":"M Goto","year":"2016","unstructured":"Goto M et al (2016) Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. Int J Cardiol 220:602\u2013607","journal-title":"Int J Cardiol"},{"issue":"12","key":"2776_CR91","doi-asserted-by":"publisher","first-page":"e0240669","DOI":"10.1371\/journal.pone.0240669","volume":"15","author":"A Daci","year":"2020","unstructured":"Daci A et al (2020) Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. PLoS One 15(12):e0240669","journal-title":"PLoS One"},{"key":"2776_CR92","doi-asserted-by":"publisher","first-page":"106818","DOI":"10.1016\/j.vph.2020.106818","volume":"136","author":"Y Ding","year":"2020","unstructured":"Ding Y et al (2020) Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation. Vascul Pharmacol 136:106818","journal-title":"Vascul Pharmacol"},{"key":"2776_CR93","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.thromres.2016.06.008","volume":"144","author":"CM Terry","year":"2016","unstructured":"Terry CM, He Y, Cheung AK (2016) Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb Res 144:106\u2013112","journal-title":"Thromb Res"},{"issue":"2","key":"2776_CR94","first-page":"a005132","volume":"4","author":"W Bergmeier","year":"2011","unstructured":"Bergmeier W, Hynes RO (2011) Extracellular matrix proteins in hemostasis and thrombosis. Cold Spring Harb Perspect in Biol 4(2):a005132","journal-title":"Cold Spring Harb Perspect in Biol"},{"issue":"1","key":"2776_CR95","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ab.2005.04.038","volume":"344","author":"RF Gerlach","year":"2005","unstructured":"Gerlach RF et al (2005) Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344(1):147\u2013149","journal-title":"Anal Biochem"},{"issue":"1","key":"2776_CR96","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2013.03.009","volume":"139","author":"GV Halade","year":"2013","unstructured":"Halade GV, Jin YF, Lindsey ML (2013) Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther 139(1):32\u201340","journal-title":"Pharmacol Ther"},{"issue":"4","key":"2776_CR97","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000499975","volume":"56","author":"M Maeda","year":"2019","unstructured":"Maeda M, Tsuboi T, Hayashi T (2019) An inhibitor of activated blood coagulation factor x shows anti-endothelial senescence and anti-atherosclerotic effects. J Vasc Res 56(4):181\u2013190","journal-title":"J Vasc Res"},{"issue":"12","key":"2776_CR98","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00125-021-05562-9","volume":"64","author":"F Pistrosch","year":"2021","unstructured":"Pistrosch F et al (2021) Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. Diabetologia 64(12):2701\u20132712","journal-title":"Diabetologia"},{"issue":"11","key":"2776_CR99","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.jacc.2003.11.062","volume":"43","author":"DS Conway","year":"2004","unstructured":"Conway DS et al (2004) Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43(11):2075\u20132082","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2776_CR100","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijcard.2013.08.078","volume":"169","author":"N Wu","year":"2013","unstructured":"Wu N et al (2013) Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol 169(1):62\u201372","journal-title":"Int J Cardiol"},{"issue":"4","key":"2776_CR101","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.hrthm.2009.12.009","volume":"7","author":"J Li","year":"2010","unstructured":"Li J et al (2010) Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 7(4):438\u2013444","journal-title":"Heart Rhythm"},{"issue":"12","key":"2776_CR102","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1111\/jth.12742","volume":"12","author":"NC Olson","year":"2014","unstructured":"Olson NC et al (2014) Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost 12(12):1993\u20132001","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2776_CR103","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.thromres.2011.04.016","volume":"128","author":"MF Matos","year":"2011","unstructured":"Matos MF et al (2011) The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: a case-control study. Thromb Res 128(3):216\u2013220","journal-title":"Thromb Res"},{"issue":"13","key":"2776_CR104","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa023153","volume":"349","author":"PS Wells","year":"2003","unstructured":"Wells PS et al (2003) Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 349(13):1227\u20131235","journal-title":"N Engl J Med"},{"issue":"1","key":"2776_CR105","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13018-018-0883-1","volume":"13","author":"CT Wu","year":"2018","unstructured":"Wu CT et al (2018) Plasma D-dimer is not useful in the prediction of deep vein thrombosis after total knee arthroplasty in patients using rivaroxaban for thromboprophylaxis. J Orthop Surg Res 13(1):173","journal-title":"J Orthop Surg Res"},{"issue":"4","key":"2776_CR106","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/jth.12515","volume":"12","author":"AT Cohen","year":"2014","unstructured":"Cohen AT et al (2014) D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 12(4):479\u2013487","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2776_CR107","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1111\/j.1538-7836.2008.03120.x","volume":"6","author":"LC Borris","year":"2008","unstructured":"Borris LC et al (2008) Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events. J Thromb Haemost 6(10):1671\u20131679","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2776_CR108","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/eurjhf\/hft125","volume":"16","author":"SH Nymo","year":"2014","unstructured":"Nymo SH et al (2014) Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail 16(1):68\u201375","journal-title":"Eur J Heart Fail"},{"key":"2776_CR109","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fcvm.2020.00114","volume":"7","author":"GL Martins","year":"2020","unstructured":"Martins GL et al (2020) Comparison of inflammatory mediators in patients with atrial fibrillation using warfarin or rivaroxaban. Front Cardiovasc Med 7:114","journal-title":"Front Cardiovasc Med"},{"key":"2776_CR110","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijcard.2021.10.025","volume":"345","author":"L Di Lullo","year":"2021","unstructured":"Di Lullo L et al (2021) New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation. Int J Cardiol 345:90\u201397","journal-title":"Int J Cardiol"},{"issue":"16","key":"2776_CR111","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1161\/CIRCULATIONAHA.113.005837","volume":"128","author":"K-C Yang","year":"2013","unstructured":"Yang K-C, Dudley SC (2013) Oxidative stress and atrial fibrillation. Circulation 128(16):1724\u20131726","journal-title":"Circulation"},{"issue":"4","key":"2776_CR112","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11239-013-1019-4","volume":"37","author":"A Caliskan","year":"2014","unstructured":"Caliskan A et al (2014) Factor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusion. J Thromb Thrombolysis 37(4):464\u2013468","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2776_CR113","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/ph11020046","volume":"11","author":"GA Richards","year":"2018","unstructured":"Richards GA et al (2018) The effects of dabigatran and rivaroxaban on markers of polymorphonuclear leukocyte activation. Pharmaceuticals (Basel) 11(2):46","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"2776_CR114","doi-asserted-by":"publisher","first-page":"e012195","DOI":"10.1161\/JAHA.119.012195","volume":"8","author":"H Ichikawa","year":"2019","unstructured":"Ichikawa H et al (2019) Rivaroxaban, a Direct factor xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. J Am Heart Assoc 8(8):e012195","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2776_CR115","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/2048872617745003","volume":"8","author":"S Korjian","year":"2019","unstructured":"Korjian S et al (2019) Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care 8(2):186\u2013193","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"8","key":"2776_CR116","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1161\/STROKEAHA.120.029628","volume":"51","author":"JF Scheitz","year":"2020","unstructured":"Scheitz JF et al (2020) High-sensitivity cardiac troponin T for risk stratification in patients with embolic stroke of undetermined source. Stroke 51(8):2386\u20132394","journal-title":"Stroke"},{"issue":"5","key":"2776_CR117","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jchf.2019.12.009","volume":"8","author":"JW Cunningham","year":"2020","unstructured":"Cunningham JW et al (2020) Natriuretic Peptide-based inclusion criteria in a heart failure clinical trial: insights from COMMANDER HF. JACC Heart Fail 8(5):359\u2013368","journal-title":"JACC Heart Fail"},{"issue":"2","key":"2776_CR118","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11239-019-02014-5","volume":"49","author":"YX Gue","year":"2020","unstructured":"Gue YX et al (2020) Rationale and design of \u201cCan Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)\u201d study\u202f: a randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. J Thromb Thrombolysis 49(2):192\u2013198","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"2776_CR119","doi-asserted-by":"publisher","first-page":"942","DOI":"10.15252\/msb.20156297","volume":"13","author":"PE Geyer","year":"2017","unstructured":"Geyer PE et al (2017) Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 13(9):942","journal-title":"Mol Syst Biol"},{"issue":"4","key":"2776_CR120","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/14789450.2015.1064771","volume":"12","author":"Y Hathout","year":"2015","unstructured":"Hathout Y (2015) Proteomic methods for biomarker discovery and validation. Are we there yet? Expert Rev Proteomics 12(4):329\u201331","journal-title":"Expert Rev Proteomics"},{"issue":"11","key":"2776_CR121","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/europace\/eum191","volume":"9","author":"P Kirchhof","year":"2007","unstructured":"Kirchhof P et al (2007) Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9(11):1006\u20131023","journal-title":"Europace"},{"issue":"6","key":"2776_CR122","doi-asserted-by":"publisher","first-page":"e010976","DOI":"10.1161\/JAHA.118.010976","volume":"8","author":"D Ko","year":"2019","unstructured":"Ko D et al (2019) Proteomics profiling and risk of new-onset atrial fibrillation: framingham heart study. J Am Heart Assoc 8(6):e010976\u2013e010976","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"2776_CR123","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.jacc.2019.01.074","volume":"73","author":"QS Wells","year":"2019","unstructured":"Wells QS et al (2019) Accelerating biomarker discovery through electronic health records, automated biobanking, and proteomics. J Am Coll Cardiol 73(17):2195\u20132205","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2776_CR124","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2217\/fca-2019-0091","volume":"16","author":"U Tantry","year":"2020","unstructured":"Tantry U et al (2020) Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. Future Cardiol 16(2):69\u201375","journal-title":"Future Cardiol"},{"issue":"2","key":"2776_CR125","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/labmed\/lmw001","volume":"47","author":"RS Riley","year":"2016","unstructured":"Riley RS et al (2016) Widely used types and clinical applications of D-dimer assay. Lab Med 47(2):90\u2013102","journal-title":"Lab Med"},{"key":"2776_CR126","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4939-7196-1_7","volume":"1646","author":"J Thachil","year":"2017","unstructured":"Thachil J, Lippi G, Favaloro EJ (2017) D-dimer testing: laboratory aspects and current issues. Methods Mol Biol 1646:91\u2013104","journal-title":"Methods Mol Biol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02776-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02776-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02776-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T18:26:19Z","timestamp":1728843979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02776-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":126,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["2776"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02776-z","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"15 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of Bayer AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}